Kerendia® Tablets for Chronic Kidney Disease in Type 2 Diabetes

What Kerendia® Is and How It Works

Kerendia (finerenone) is a non-steroidal mineralocorticoid receptor antagonist used to reduce the risk of kidney function decline and cardiovascular events in adults with chronic kidney disease (CKD) associated with type 2 diabetes. It is an oral tablet taken once daily in 10 mg and 20 mg strengths. Many patients compare Kerendia cost options when paying without insurance, and YouDrugstore offers Canadian pricing on this prescription medicine.

YouDrugstore is a licensed Canadian pharmacy headquartered in Manitoba; prescriptions are reviewed by licensed pharmacists before dispensing. We work with vetted international partner pharmacies when needed so patients can access authentic brand medications at fair prices and with a broad selection.

By blocking mineralocorticoid receptor overactivation in the kidneys and heart, finerenone helps limit inflammation and fibrosis. This mechanism supports slower CKD progression and lowers risks of sustained eGFR decline, kidney failure, heart attack, and hospitalization for heart failure. Kerendia is used alongside standard care, which often includes an ACE inhibitor or ARB and good blood pressure and glucose control.

Dosage and Usage

Kerendia tablets are taken once daily, with or without food. The starting dose depends on kidney function and blood potassium. Follow the prescribed plan and the Kerendia prescribing information.

• Starting dose: 20 mg once daily if eGFR is ≥60 mL/min/1.73 m² and potassium is ≤4.8 mEq/L.
• Starting dose: 10 mg once daily if eGFR is 25 to <60 mL/min/1.73 m² and potassium is ≤4.8 mEq/L.
• Do not initiate if eGFR <25 mL/min/1.73 m² or if serum potassium is >5.0 mEq/L.
• Target dose: 20 mg once daily, if potassium remains in an acceptable range.
• Monitor potassium and eGFR at baseline and about 4 weeks after starting or changing dose, then periodically.
• Missed dose: take the next dose at the usual time; do not double doses.
• Administration: swallow tablets whole with water. Avoid grapefruit or grapefruit juice.

• Storage: keep tablets at 20–25°C (68–77°F); excursions 15–30°C (59–86°F).
• Store in the original container, tightly closed, away from moisture and light.
• Keep out of reach of children and pets.
• Travel: carry in hand luggage with the pharmacy label; avoid heat and freezing.
• Do not use past the labeled expiry date.

Benefits and Savings

Kerendia uses a selective, non-steroidal approach to mineralocorticoid receptor blockade. It reduces albuminuria and slows CKD progression in type 2 diabetes. It can also lower the risk of cardiovascular outcomes like hospitalization for heart failure. Once-daily dosing is simple, and tablets are available in 10 mg and 20 mg strengths for flexible titration.

Buying from Canada can offer meaningful savings. Many customers see 60–80% lower prices compared with typical US costs, which helps those managing Kerendia price expectations, including patients paying without insurance. Multi-month supplies may reduce the per-month cost, and reorder reminders can help maintain therapy without gaps.

To see seasonal offers, visit our kerendia coupon page.

Side Effects and Safety

• Most common: increased potassium (hyperkalemia).
• Other common: low blood pressure, dizziness, mild kidney function changes on labs.
• Less common: fatigue, diarrhea or constipation, headache.
• Lab monitoring: routine potassium and eGFR checks are recommended.

Serious risks include hyperkalemia that may cause cardiac rhythm problems and, rarely, acute kidney injury. Risk increases with reduced kidney function or interacting drugs. Use with insulin or sulfonylureas does not directly cause hypoglycemia, but overall diabetes regimens may require monitoring to avoid low blood sugar when other agents are adjusted. Avoid strong CYP3A4 inhibitors (for example, itraconazole, clarithromycin) and grapefruit. Avoid strong CYP3A4 inducers (for example, rifampin, carbamazepine, St. John’s wort). Use with other potassium-raising drugs or potassium-sparing diuretics needs caution. Severe hepatic impairment and pregnancy or breastfeeding require prescriber guidance.

Onset Time

Albuminuria reductions can appear within the first 1–3 months as dosing stabilizes and potassium remains in range. Meaningful effects on eGFR slope and cardiovascular outcomes accrue over months to years. Regular follow-up and labs help confirm response and ongoing safety.

Compare With Alternatives

Spironolactone is a steroidal mineralocorticoid receptor antagonist that can help with resistant hypertension and heart failure. It is effective but has more hormonal side effects, such as gynecomastia. Kerendia is non-steroidal and was studied specifically in CKD with type 2 diabetes to reduce kidney and cardiovascular events.

Eplerenone is another steroidal agent with fewer hormonal effects than spironolactone but still differs from finerenone in selectivity and evidence for CKD in diabetes. Kerendia focuses on kidney and cardiac fibrosis pathways with a favorable selectivity profile.

SGLT2 inhibitors provide complementary benefits in CKD with type 2 diabetes. Empagliflozin offers kidney and cardiovascular protection and can pair well with finerenone when appropriate. See Jardiance® for details on that class.

Renin-angiotensin system blockers remain foundational. Patients are often on an ACE inhibitor or ARB. Some take a telmisartan-based product; see Micardis® Plus for an example that combines telmisartan with hydrochlorothiazide. Kerendia is added to this backbone in eligible patients to further reduce risk.

Combination Therapy

• Kerendia plus an ACE inhibitor or ARB: standard background therapy in CKD with type 2 diabetes.
• Kerendia plus an SGLT2 inhibitor: complementary kidney and heart protection when appropriate.
• Diabetes agents (metformin, GLP-1 receptor agonists, insulin): continue as indicated for glucose goals.
• Monitor potassium more often when combining with agents that raise potassium; dose adjustments or temporary holds may be needed.

Patient Suitability and Cost-Saving Tips

Kerendia indication: reduce risk of sustained eGFR decline, kidney failure, and cardiovascular events in adults with CKD associated with type 2 diabetes. Candidates have albuminuria and are typically on stable ACE inhibitor or ARB therapy. Baseline potassium should be ≤5.0 mEq/L, and eGFR should be ≥25 mL/min/1.73 m² at initiation.

Who may not be a candidate: those with high baseline potassium, eGFR <25 mL/min/1.73 m², severe hepatic impairment, or those taking strong CYP3A4 inhibitors or inducers. Use caution with other potassium-raising drugs. Follow the Kerendia prescribing information and prescriber guidance for monitoring and dose changes.

Cost-savings: check current Kerendia tablet price for 10 mg and 20 mg on the product page. Ordering a longer supply can lower the monthly average cost. Set up simple reorder reminders so the next refill is ready before running low. These steps can help manage the overall cost of Kerendia medication, including patients who pay without insurance.

Other practical points: tablets come in 10 mg and 20 mg strengths, so titration is straightforward. There is no generic for Kerendia yet; finerenone is the active ingredient. The Kerendia manufacturer is Bayer, which provides consumer and prescriber resources online.

Authoritative Sources

Kerendia patient site (manufacturer)

FDA Prescribing Information for finerenone

Health Canada Drug Product Database search

Order Kerendia® from YouDrugstore: add to cart, upload your prescription, and we ship with prompt, express shipping.

This material is for educational purposes only and does not replace advice from a qualified healthcare professional.